Thirteen months ended December 31, 2021
The company recorded revenues of over $21 million, net income of ($10 million), EBITDA of ($8.2 million) and adjusted EBITDA of ($1.7 million). Total operating expenses for the period ended December 31, 2021 were $6.5 million, largely due to professional fees related to various legal and accounting activities for the reverse takeover (RTO ) and an acquisition made during the period. The Company also recorded a non-cash amortization cost of $2 million related to the Company’s equipment, right-of-use and intangible assets acquired during the period. Another significant item of note is the $1.7 million RTO listing expense representing ScreenPro’s costs to obtain listing on the CSE. The company’s cash flow decline of ($238,288) is due to the company’s investment in the purchase of $1.6 million of Covid-19 testing inventory and $797,148 of goods and laboratory equipment for operations to drive business and profits.
“The company has built a solid and successful foundation for Covid testing. Prominent film and production companies across Canada trust ScreenPro to keep them safe throughout the pandemic. As the need for Covid testing grows this year we look forward to focusing on not only accelerating our testing services, but also diversifying the company into other health screening products that will be just as profitable as Covid testing,” said Lena Kozovski , CEO of the company.
“We continued our core business momentum and entered 2022 with strong Covid testing numbers. We are proud of our team who achieved record revenues from Covid testing, which generated revenues of over 21 The Company is focused on aligning with our shareholders to maximize shareholder value and continue to be opportunistic and expand our product offerings in 2022,” said Michael Yeung, Chairman of the Company.
The following is selected financial information for the financial results ending December 31, 2021. Please see the entire Fourth Quarter 2021 filing, which is available under ScreenPro’s profile at www.sedar.com.
Financial highlights for thirteen months, financial results ended December 31, 2021:
|December 31, 2021|
|Total current liabilities||$3,969,395|
The following table summarizes revenue, net loss, EBITDA* and adjusted EBITDA* for the years ended December 31, 2021 and 2020. All figures are in Canadian dollars unless otherwise indicated:
|December 31, 2021||November 30, 2020|
|Depreciation and amortization||$1,995,787||$45,769|
|Base compensation in shares||—||$548,500|
|Excess consideration paid on net assets acquired||$4,777,912||—|
The company’s financial performance improved greatly in the third and fourth quarters, driven by growth from its core business in Covid testing. The tests continue to have strong demand, which further improves the Company’s financial situation. From December 2021 to March 2022, the Company administered approximately 82,636 Covid tests. In the first quarter of 2022, ScreenPro saw continued growth in its test count.
The test numbers are as follows:
- December 2021 resulted in a total of 14,202 Covid-19 tests
- January 2022 resulted in a total of 19,446 Covid-19 tests
- February 2022 resulted in a total of 23,655 Covid-19 tests
- March 2022 resulted in a total of 25,333 Covid-19 tests
Due to the company’s focus on the film industry, strong testing revenue is expected in 2022 as the company does not foresee any near-term process change in the film industry. ScreenPro recently announced that as of April 8, 2022, the company has secured a total of 21 new productions so far for the first quarter of FY22. As Canadians deal with an increase in COVID-19 cases, the company remains focused in 2022 to further capitalize on testing services as there is increased demand for testing in the film and production industry and in the community.
The company continues to diversify its product and service offerings and expects significant growth as it expands further into the medical screening space with the acquisition of Add Biomedical.Add bio”) and potentially other future opportunities. Add Bio has recently submitted applications to the Canadian Intellectual Property Office (CIPO) and United States Patent and Trademark Office (USPTO) and plans to enter the breast cancer screening industry.
The Board of Directors has mandated ScreenPro management to continue to focus on revenue growth and improve profitability in 2022 through product and service diversification. Strategies to achieve the goals would include organic growth of its subsidiaries, acquisitions, mergers or joint ventures of businesses that are synergistic and have potential value for ScreenPro. The Company anticipates an exciting 2022 filled with activity from its operational and corporate objectives, in particular the growth of its Covid testing and its expansion into other testing products and services that will be profitable and add value. of the society.
About Screen Pro
ScreenPro is a medical screening and technology company that provides turnkey screening solutions with its proprietary medical alert software. ScreenPro’s unique access to several manufacturers of high-quality test kits and its strategic partnership with laboratories in British Columbia, Ontario and Quebec allow ScreenPro to be a national full-service testing provider. COVID and breast cancer screening solutions across Canada. Additionally, ScreenPro has its own doctor and nursing professionals with field support staff and transportation, with access to high quality PPE to ensure customers are protected in all aspects of their health needs. test.
For more information about ScreenPro and other company information, please visit the company’s website at www.screenprosecurity.com
For further information on the Company, please see the Company’s profile on SEDAR at www.sedar.com.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Lena Kozovski, CEO
Email: [email protected]
Certain statements in this press release may constitute forward-looking information, including statements relating to expectations regarding the acquisition and business of Concierge Medical Consultants Inc. and the future development of ScreenPro’s business. Forward-looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “have the intention to”, “should”, and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. ScreenPro’s actual results could differ materially from those anticipated in this forward-looking information due to regulatory decisions, competitive factors in the industries in which ScreenPro operates, prevailing economic conditions, changes in ScreenPro’s strategic growth plans and other factors, many of which are beyond ScreenPro’s control. ScreenPro’s management believes that the expectations reflected in the forward-looking information presented herein are reasonable, but no assurance can be given that such expectations will prove to be correct and such forward-looking information should not be relied upon unduly. Any forward-looking information contained in this press release represents ScreenPro’s expectations as of the date hereof and is subject to change after such date. ScreenPro disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
NON-IFRS FINANCIAL MEASURES
The Company has included non-IFRS performance measures throughout this press release, including (a) earnings before interest, taxes, depreciation and amortization (“EBITDA”); (b) Adjusted EBITDA which is EBITDA adjusted for the gain (loss) on the change in fair value of the Company’s investment properties and the gain (loss) on the change in fair value of instruments derivatives; and (c) book value per share which is calculated as equity attributable to shareholders of Datametrex AI Limited divided by the total number of ordinary shares outstanding at the end of the reporting period. These non-IFRS financial measures do not have standardized meanings as prescribed by International Financial Reporting Standards (“IFRS”) and therefore are unlikely to be comparable to similar measures presented by other issuers. Accordingly, these performance measures are intended to provide additional information and should not be considered in isolation or as a substitute for performance measures prepared in accordance with IFRS. Management uses EBITDA measures to measure earnings trends for business units and segments of the consolidated group as they eliminate the effects of financing decisions. Certain investors, analysts and others use these non-IFRS financial measures to assess the Company’s financial performance. These non-IFRS financial measures have not been presented as an alternative to net income or any other financial measure of performance prescribed by IFRS. The reconciliation of non-IFRS measures has been provided in the Company’s MD&A, as applicable, filed under the Company’s profile at www.SEDAR.COM.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/122456